Market Access Strategy for BIOTECH, MEDTECH and DIGITAL HEALTH STARTUPS FRANCE GERMANY SWITZERLAND NOVEMBER 23 – 24, 2023 STRASBOURG + ONLINE MORE INFOS
HOME
Mission: IOME Bio aims to harness unique mechanistic insights to overcome resistance to checkpoint inhibitors and deliver meaningful benefits for cancer patients
SCIENCE
IOME Bio builds on foundational insights and IP from world-renowned immuno-oncology researchers, and has an exclusive option to licence new IP arising from ongoing sponsored research at Harvard
ABOUT US
We are a venture-backed Harvard spin-off pursuing novel immuno-oncology targets with first-in-class antibodies
Our foundational science was discovered by Arlene Sharpe and Dennis Kasper at Harvard, and Gordon Freeman at the Dana-Farber Cancer Institute
We are addressing resistance to PD-1 blockade through proprietary mechanistic insights
We are centrally located in the beautiful city of Strasbourg, embedded in a vibrant health innovation ecosystem.
CONTACT
OUR LATEST NEWS
IOME bio will be at BIO EUROPE : a gateway to the Global Biopharma Community
BIO-Europe convenes over 5,500 attendees, representing 60 countries and 2,220+ companies, making the event the industry’s largest gathering of biopharma professionals in Europe. KNOW MORE
Prestigious Gustave Roussy Cancer center researchers
publish positive editorial about Harvard’s nature published paper bringing additional external validation to IOME Bio’ science. READ